PND1 A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients With Relapsing-Remitting Multiple Sclerosis
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.760
https://www.valueinhealthjournal.com/article/S1098-3015(12)00825-X/fulltext
Title :
PND1 A Risk-Benefit Analysis of Natalizumab Across PML Risk Sub-Groups in Patients With Relapsing-Remitting Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00825-X&doi=10.1016/j.jval.2012.03.760
First page :
A140
Section Title :
Neurological Disorders
Open access? :
No
Section Order :
239